Corporate Governance Overview

Nationality: Swiss
Year of birth: 1952

Chairman of the Board of Directors of Lonza Group Ltd (since 2018), Independent member of the Board of Directors of Lonza Group Ltd (since April 2017).

On 12 November 2019, Albert M. Baehny took on the responsibilities as CEO ad interim until his successor, Pierre-Alain Ruffieux, assumed the position on 1 November 2020.

Albert M. Baehny holds a degree in biology from the University of Fribourg (CH).

Current Activities and Functions

Public Company Boards

• Member of the Board of Directors of Investis Group Holding SA (since 2016)
• Chairman of the Board of Directors of Geberit AG (since 2011)

Former Activities and Functions

• CEO ad interim of Lonza Group Ltd (2019–2020)
• CEO of Geberit Group (2005–2014)
• Head of Group Division Marketing and Sales Europe for Geberit Group (2003–2004)
• Senior Vice-President at Wacker Chemie AG (2001–2002)
• Various Marketing, Sales, Strategic Planning and Global Management Positions with:
  • Vantico (2000–2001)
  • Ciba-Geigy / Ciba Specialty Chemicals (1994–2000)
  • Dow Chemicals Europe (1981–1993)
  • Serono-Hypolab (1979–1981)

Nationality: Swiss
Year of birth: 1959

Vice-Chairman of the Board of Directors of Lonza Group Ltd (since April 2020); Independent member of the Board of Directors of Lonza Group Ltd (since April 2016).

On 12 November 2019, Christoph Mäder was appointed Lead Independent Director by the Board.

Christoph Mäder holds a Master’s degree in law from the University of Basel (CH) and is admitted to the Swiss Bar.

Current Activities and Functions

Public Company Boards

• Member of the Board of EMS Chemie Holding AG (since 2018)
• Member of the Board of Directors Baloise Holding AG (since 2019)

Further Appointments

• President of Economiesuisse (since 2020)
• Member of the Board of Directors Assivalor AG (since 2019)
• Member of the Advisory Board of Accenture Switzerland (since 2019)
• Partner at the law firm Becker-Gurini-Hanhart-Vogt (since 2019)
• Member of the Council of Schweizer Jugend forscht (since 2018)
• Member of the Advisory Board of Vereinigung Schweizerischer Unternehmen in Deutschland (since 2016)
• Member of the Advisory Board of Loeba GmbH (since 2014)

Former Activities and Functions

• Member of the Group Executive Committee of Syngenta (2000–2018)
• Member of the Board Committee of economiesuisse (2008–2019)
• Vice-Chairman of economiesuisse (2011–2017)
• Member of the Executive Board of the Business and Industry Advisory Committee (BIAC) for the Organization for Economic Co-operation and Development (OECD) (2012–2016)
• Member of the Board of scienceindustries (2006–2018)
• Member of the Board of the Basel Chamber of Commerce (2002–2018)
• Head of Legal & Public Affairs for Novartis Crop Protection AG (1999–2000)
• Senior Corporate Counsel for Novartis International AG (1992–1998)

Nationality: Swiss
Year of birth: 1950

Independent member of the Board of Directors of Lonza Group Ltd (since April 2013).

Werner Bauer holds a diploma and PhD in chemical engineering from the University of Erlangen-Nürnberg  (DE). He has received several scientific honors, among others the BioAlps Award 2011 and Honorary Senator from the Technical University of Munich (DE).

Current Activities and Functions

Public Company Boards

• Member of the Board of Directors of SIG Combibloc Group AG (since 2018)
• Vice-Chairman of the Board of Directors of Givaudan SA (since 2014)

Further Appointments

• Member of the Board of Directors of the Urs Bühler Innovation Fund (since 2019)
• Vice-Chairman of the Supervisory Board of Bertelsmann SE & Co. KGaA (since 2012)
• Chairman of the Board of Trustees of the Bertelsmann Foundation (since 2003)

Former Activities and Function

• Member of the Supervisory Board of GEA Group AG (2011–2018)
• Chairman of the Supervisory Board of Nestlé Deutschland AG (2007–2017)
• Executive Vice-President of Nestlé SA, Head of Innovation, Technology, Research and Development (2007–2013)
• Executive Vice-President of Nestlé SA, Head of Technical, Production, Environment, Research & Development (2002–2007)
• Various managerial positions of increasing responsibility at Nestlé (1990–2002)
• Chairman of the Board of Directors of Galderma Pharma SA (2011–2014)
• Member of the Board of Directors of L’OREAL, France (2005–2012)
• Member of the Board of Directors of Alcon Inc., Switzerland (2002–2010)
• Director of the Fraunhofer Institute for Food Technology & Packaging and Professor in Bioprocess Technology at Technical University Munich (DE) (1985–1990)
• Professor of Chemical Engineering at the Technical University of Hamburg (DE) (1980–1985)

Nationality: Austrian
Year of birth: 1968

Independent member of the Board of Directors of Lonza Group Ltd (since April 2020).

Non-Executive Director and Corporate Finance Adviser, who brings more than 25 years of experience in the fields of manufacturing, biotech, pharmaceuticals and banking. Ms Deuring currently serves on the board of several companies including Axpo, Bilfinger and Elementis. Her Board memberships span the energy, plant engineering, chemical and biopharmaceutical sectors. She received her Master of Science in Chemistry from Université Louis Pasteur, Strasbourg in 1994. In 1996 she received her Master in Business Administration from INSEAD, Fontainebleau (FR).

Current Activities and Functions

Public Company Board Mandates

• Member of the Board of Directors, Member of the Audit Committee of Axpo Holding AG (since 2017)
• Member of the Board of Directors, Member of the Audit and Remuneration Committees of Elementis PLC (since 2017)
• Supervisory Board Member, Member of the Audit Committee of Bilfinger SE (since 2016)

Further Mandate

• Member of the Board of Directors of PIQUR Therapeutics AG (since 2019)

Activity

• Independent Corporate Finance Adviser (since 2014)

Former Activities and Functions

• Member of the Board of Directors of Selecta AG (2020)
• Supervisory Board Member (Beirat) of Röchling Group SE & Co. KG (2016–2019)
• Head of Corporate Advisory Group Europe, Managing Director Wealth Management Division of UBS AG (2011–2014)
• Managing Director Investment Banking, Head Healthcare and Chemicals M&A of Bankhaus Sal. Oppenheim Jr & Cie (2007–2009)
• Vice Director, Corporate Finance, Mergers & Acquisitions; Vice Director, Diagnostics Division, Business Development for F. Hoffman-La Roche AG (2003–2007)
• Founder, Owner Manager and Board Member of CoCap AG (1998–2003)
• Consultant of McKinsey & Company (1997–1998)
• Managing Director of K. Deuring & Co (1993–1997)

Nationality: German-Brazilian
Year of birth: 1960

Independent member of the Board of Directors of Lonza Group Ltd (since May 2018).

Angelica Kohlmann holds a MD and doctorate in medicine from Hamburg University (DE).

Current Activities and Functions 

• Member International Advisory Board IE University and Business School, Madrid (since 2017)
• Chairperson Board of Directors, Bloom Diagnostics AG (since 2014)
• Chairperson Board of Directors, Kohlmann & Co AG (since 2013)
• International investor in biotech and tech, based in Switzerland (since 2014)
• Board Observer Teralytics AG (since 2017)
• Chairperson of the Advisory Board Peter Drucker Society Europe / Global Peter Drucker Forum, Vienna (since 2009)

Former Activities and Functions 

• Member Advisory Board UBS Unique (2017–2018)
• Director Trinnacle Fund Ltd (2016–2017)
• Member Board of Directors Teralytics AG (2013–2016)
• Founder & CEO Ifitech GmbH, Germany (2010–2017)
• International investor in biotech and tech, based in Germany (2000–2013)
• International consultant for strategy, management, investments and restructuring (1992–1999)
• Head global restructuring Behringwerke AG, Germany (1990–1992)
• Member Board Staff Hoechst AG, Germany (1988–1990)
• International Marketing Group Leader at Behringwerke AG (1986–1988)
• MD Anderson Cancer Center, Houston and Memorial Sloan Kettering Cancer Center, New York, USA – various cancer research functions

Nationality: British
Year of birth: 1960

Independent member of the Board of Directors of Lonza Group Ltd (since April 2014).

Barbara Richmond holds a first-class degree in management science from the University of Manchester Institute of Science and Technology in England. Barbara Richmond has substantial knowledge as a financial expert, demonstrated by her roles as Chief Financial Officer for various companies. She is a Fellow of the Institute of Chartered Accountants in England and Wales.

Current Activities and Functions

Public Company Boards

• Group CFO of Redrow plc (since 2010)

Former Activities and Functions

• Group CFO of Inchcape plc (2006–2009)
• Non-Executive Director and Audit Committee Chair of Scarborough Building Society until its merger with The Skipton Building Society (2005–2009)
• Non-Executive Director, Senior Independent Director and Audit Committee Chair of Carclo Group plc (2000–2006)
• Group CFO of Croda International plc (1997–2006) with dual role as Group CFO and President of Active Ingredients and Industrial Chemicals from 2002 to 2006
• Group CFO of Whessoe plc in 1993 (1993–1997)
• Various financial roles in Alstom Group SA (1987–1992)
• Auditor and management consultant for Arthur Andersen (1981–1984)

Nationality: German
Year of birth: 1958

Independent member of the Board of Directors of Lonza Group Ltd (since April 2014). Jürgen Steinemann holds a degree in Economics and Business Management from the European Business School in Wiesbaden (DE), London (UK) and Paris (FR).

Current Activities and Functions

Public Company Boards

• Member of the Board of Directors of Barry Callebaut AG (since 2015)
• Chairman of the Supervisory Board of Metro AG (since 2015)

Further Appointments

• Investor in food and agro businesses
• Managing Director of JBS Holding GmbH (since 2017)
• Chairman of the Supervisory Board of Bankiva B.V. (since 2017)
• Member of the Advisory Board of Tower Brook Capital Partners LP (since 2017)
• Member of the Supervisory Board of Big Dutchman AG (since 2015)

Former Activities and Functions 

• Chief Executive Officer of Barry Callebaut Ltd (2009–2015)
• Member of the Board of the Swiss-American Chamber of Commerce (2011–2015)
• Member of the Executive Board and Chief Operating Officer of Nutreco (2001–2009)
• Chief Executive Officer of Loders Croklaan (1999–2001)
• Various senior positions in business-to-business marketing and sales with the former Eridania Béghin-Say Group, ultimately in the «Corporate Plan et Stratégie» unit at the head office in Paris (1990–1998)

Nationality: Belgian
Year of birth: 1972

Independent member of the Board of Directors of Lonza Group Ltd (since May 2018).

Olivier Verscheure holds a PhD in computer science from the Swiss Federal Institute of Technology, Lausanne (CH) (EPFL, July 1999).

Current Activities and Functions 

• Expert in the Strategy Working Group on Data, Computing and Digital Research lnfrastructures in the State Secretariat for Education, Research and Innovation (SERI) (since 2019)
• Member of the Foundation Council of SWITCH (since 2019)
• Founder and Executive Director of the Swiss Data Science Center, a joint venture between EPFL and ETH Zürich (since 2016)
• Member of the Executive Committee of Personalized Health and Related Technologies (PHRT), an ETH Domain Strategic Focus Area (since 2017)
• Co-academic Director, Certificate of Advanced Studies (CAS), Data Science and Management, HEC Lausanne and EPFL (since 2018)

Former Activities and Functions 

• Lab Program Director and Senior Research Manager at IBM Research Ireland (2010 – 2016)
• Research Manager and Senior Member of the Research Staff at the IBM T.J. Watson Research Center (1999 – 2010)

Nationality: Swiss
Year of birth: 1954

Vice-Chairman of the Board of Directors of Lonza Group Ltd (April 2014 until April 2020), Independent member of the Board of Directors of Lonza Group Ltd (March 2008 until April 2020).

Patrick Aebischer holds a doctorate in medicine from the University of Geneva (CH). He has received numerous honors, including the Robert Bing Prize of the Swiss Academy of Medicine and the Pfizer Foundation Prize for Clinical Neurosciences.

Current Activities and Functions 

Public Company Boards

• Member of the Board of Directors of Logitech SA (since 2016)
• Member of the Board of Directors of Nestlé SA (since 2015)

Further Appointments

• Chairman of the Board of Directors of Arctos SA (since 2019)
• Senior Partner of NanoDimension Management Limited (since 2017)
• Scientific technical committee member of the Italian Institute of Technology (since 2015)
• Chairman of the Novartis Venture Fund (since 2014)
• Member of the Singapore Biomedical Sciences International Advisory Council (since 2013)
• Chairman of the Board of Amazentis SA (since 2007)
• Professor of Neurosciences, Swiss Federal Institute of Technology Lausanne (EPFL) (since 2000)

Former Activities and Functions 

• Senate member of the Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) (2016–2019)
• Representative of the EPFL on the boards of various Swiss foundations
• President of the Swiss Federal Institute of Technology of Lausanne (EPFL) (2000–2016)
• Member of the Foundation Board of the World Economic Forum (2013–2016)

Nationality: Dutch
Year of birth: 1954

Margot Scheltema holds a doctorate in international law from the University of Amsterdam and a Master of International Affairs (MIA) from Columbia University in New York (USA). Margot Scheltema has substantial knowledge as a finance, corporate governance and risk management expert, demonstrated by her operative roles in finance and management and supervisory roles in the financial sector (bank, central bank, insurance and pension funds).

Current Activities and Functions 

• NEDAP (NE Director) NV (since 2018)

Further Appointments

• Vice-chair of the Supervisory Board of the Dutch Central Bank (since 2015) (financial institution)
• Member of the Central Plan Committee Dutch Planning Bureau (since 2014)
• Chair of the Monitoring Committee of the Dutch Pension Fund Code (since 2014)
• Council to the Enterprise Chamber of the Amsterdam Court of Appeal (since 2013)
• Member of the Supervisory Board of Warmtebedrijf Rotterdam (since 2011)
• Member of the Supervisory Board of TNT Express (since 2011)

Former Activities and Functions 

• Vice-Chair of the Supervisory Board of Triodos Bank (2006–2015)
• Member of the Supervisory Board of ASR NV (2008–2015)
• External Member of the Audit Committee of the Dutch pension fund ABP (2010 to July 2014) (financial institution)
• Member of the Supervisory Board of the Rijksmuseum (2007–2015)
• Member of the AFM External Reporting Committee (2006–2012)
• Finance Director of Shell Nederland BV (2004–2008)
• Various managerial positions in finance within the Shell Group (1985–2004) including Senior M&A Adviser for Shell Oil Products Latin America

Nationality: Moroccan, Belgian, US-American
Year of birth: 1959

Independent member of the Board of Directors of Lonza Group Ltd (April 2020 until May 2020).

Dr Moncef Slaoui has extensive experience from his career with GlaxoSmithKline spanning nearly 30 years. In this time, he held a number of leadership positions, including Member of the Board of GSK PLC, Chairman of Pharmaceutical R&D, and Chairman of Global Vaccines. Currently, Dr Slaoui is partner at Medicxi, a venture capital firm specializing in seed, Series A, early stage and late stage life sciences investments. He also sits on various biotechnology companies’ boards. Dr Slaoui received his Ph.D. in Molecular Biology and Immunology from Brussels University in 1983. He later received an accelerated Master of Business Administration from IMD in Lausanne (CH) in 1998.

Current Activities and Functions 

Further Mandates

• Chairman of Monopteros (A Medicxi Company) (since 2018)
• Chairman of Divide & Conquer (A Medicxi Company) (since 2017)
• Chairman of Sutrovax (since 2017)
• Chairman Galvani Bioelectronics (since 2016)
• Chairman of Clasado (since 2017)

Activity

• Partner at Medicxi (since 2017)

Former Activities and Functions 

• Independent Member of the Board of Directors of Moderna (2017–2020)
• Member of the Advisory Board of the Qatar Foundation (2009–2020)
• Member of the Board of Directors of International AIDS Vaccines Initiatives (2015–2017)
• Member of the Board of GSK PLC (2006–2017)
• Chairman, Global Vaccines of GSK PLC (2009–2017)
• Chairman, Global Research & Development of GSK PLC (2006–2015)
• Various leadership roles in Research & Development including Worldwide Business Development & External Alliances (1988–2003)

Nationality: Swiss
Year of birth: 1969

Chief Executive Officer (CEO) and Member of the Executive Committee (since November 2020).

Pierre-Alain Ruffieux holds a doctorate in Biotechnology and a master’s degree in Chemical Engineering and Biotechnology from the Swiss Federal Institute of Technology (EPFL), Lausanne (CH).

Former Activities and Functions 

• Head of Global Pharma Technical Operations & Member Pharma Executive Team, F. Hoffmann-La Roche (2017–2020)
• Head of Quality and Compliance, Global Pharma Technical Operations, F. Hoffmann-La Roche (2015–2017)
• Head of Quality, Pharmaceutical Division & Member Pharmaceutical Executive Committee, Novartis Pharmaceuticals (2012–2015)
• Head of Global Pharma Technical Operations & Biologics Quality Assurance, Novartis Pharmaceuticals (2010–2012)
• Global Head of Quality for Biopharmaceutical, Novartis Pharmaceuticals (2009–2010)
• Various positions in technical development and manufacturing at Novartis Pharmaceuticals & Sandoz, Novartis Group (2003–2009)
• Various positions in technical development and manufacturing at Serono (now Merck Serono) (1998–2003)

Nationality: Swiss / Mexican
Year of birth: 1962

Chief Financial Officer (CFO) and Member of the Executive Committee (since October 2016).

Rodolfo J. Savitzky holds a degree in Industrial and Systems Engineering from the Tecnológico de Monterrey (MX) and an MBA in Finance and Economics from the University of Chicago (USA).

Former Activities and Functions 

• Vice-President Controller, Lonza Pharma & Biotech (2015–2016)
• Division CFO, Novartis Animal Health (2011–2015)
• Business Unit Head of Finance, Novartis Animal Health (2006–2011)
• Head of Strategic Planning and Analysis, Novartis Pharmaceuticals (2004–2005)
• Head of Business Planning and Analysis, Novartis Pharmaceuticals (2003)
• Head of Finance Ophthalmics Business Unit, Novartis Pharmaceuticals (2002)
• Various positions at P&G (1984–2001)

Nationality: British
Year of birth: 1972

Chief Human Resources Officer (CHRO) and Member of the Executive Committee (since May 2020).

Caroline Barth holds a degree in European Business Studies from the University of Sunderland (UK) and an MBA from The Open University (BE).

Former Activities and Functions 

• Global Head of Human Resources, Pharma, Novartis Pharma AG (2016–2020)
• Global Head Pharma Strategy, Novartis, Pharma AG (2019)
• Global Head of Human Resources, Pharma Manufacturing and Quality, Novartis Pharma AG (2014–2016)
• Global Head of Human Resources, Central & Eastern Europe, Novartis Pharma AG (2013–2014)
• VP, Human Resources Canada Pharma & Corporate HR Leader, Novartis Pharma AG (2010–2013)
• Head of Talent Management, Organizational Development & Staffing, Europe, Novartis Pharma AG (2008–2010)
• Head of Human Resources Global IT, Novartis Pharma AG (2006–2008)
• Human Resources Integration Leader, Novartis Pharma AG (2004–2006)
• HR Communications Leader, EMEA & APAC, Cisco Systems (2001–2003)
• HR Generalist, Emerging Markets, Cisco Systems (1997–2001)

Nationality: Swiss
Year of birth: 1966

Chief Operating Officer (COO) Pharma & Biotech Segment and Member of the Executive Committee (since March 2019).

Stefan Stoffel holds a Bachelor’s degree in engineering from Lucerne University of Applied Sciences and Arts.

Former Activities and Functions 

• Head of Lonza Pharma & Biotech Strategic Growth Investments and Ibex^® Solutions (2016–2019)
• Head of Lonza Pharma & Biotech Operations (2013–2016)
• General Manager of Lonza Chemical Operations Business Unit (2010–2013)
• Head of Lonza’s Small Molecules Exclusive Synthesis Business Unit (2009–2010)
• Head of Operations for Lonza’s Small Molecules Exclusive Synthesis Business Unit (2007–2009)
• Various positions at Lonza in Engineering & Maintenance, Technical Management, Production and Operations Management for Lonza AG and Lonza Inc. (1991–2007)

Nationality: German
Year of birth: 1968

Chief Operating Officer (COO) Specialty Ingredients Segment (January 2016 until July 2020) and Member of the Executive Committee (July 2014 until July 2020).

Sven Abend holds a Ph.D. in chemistry from the Christian-Albrechts-Universität in Kiel and a post-doctorate from the Department of Physics & Astronomy at the University of New York in Stony Brook (USA).

Former Activities and Functions 

• CEO of Kolb Ltd in Hedingen (CH) (2012–2014)
• Business Manager for Kolb’s divisions focusing on specialty surfactants and custom manufacturing (2010–2012)
• Several senior positions in Global Product Management and ultimately as Director of Corporate Key Account Management at Cognis GmbH in Germany (2003–2010)
• Project Scientist for the R&D Home & Personal Care business at Unilever in the UK (2000–2003)

Nationality: Swiss
Year of birth: 1952

Chairman of the Board of Directors of Lonza Group Ltd (since 2018), Independent member of the Board of Directors of Lonza Group Ltd (since April 2017).

On 12 November 2019, Albert M. Baehny took on the responsibilities as CEO ad interim until his successor, Pierre-Alain Ruffieux, assumed the position on 1 November 2020.

Albert M. Baehny holds a degree in biology from the University of Fribourg (CH).

Current Activities and Functions

Public Company Boards

• Member of the Board of Directors of Investis Group Holding SA (since 2016)
• Chairman of the Board of Directors of Geberit AG (since 2011)

Former Activities and Functions

• CEO ad interim of Lonza Group Ltd (2019–2020)
• CEO of Geberit Group (2005–2014)
• Head of Group Division Marketing and Sales Europe for Geberit Group (2003–2004)
• Senior Vice-President at Wacker Chemie AG (2001–2002)
• Various Marketing, Sales, Strategic Planning and Global Management Positions with:
  • Vantico (2000–2001)
  • Ciba-Geigy / Ciba Specialty Chemicals (1994–2000)
  • Dow Chemicals Europe (1981–1993)
  • Serono-Hypolab (1979–1981)